Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - Other
Ratios

Bristol Myers Squibb (BMYMP) R&D In Process (2021 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed R&D In Process for 5 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • Quarterly R&D In Process rose 4543.33% to $1.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 billion through Dec 2025, down 72.17% year-over-year, with the annual reading at $3.7 billion for FY2025, 72.18% down from the prior year.
  • R&D In Process for Q4 2025 was $1.4 billion at Bristol Myers Squibb, up from $633.0 million in the prior quarter.
  • The five-year high for R&D In Process was $12.9 billion in Q1 2024, with the low at $6.0 million in Q1 2021.
  • Average R&D In Process over 5 years is $999.1 million, with a median of $225.0 million recorded in 2024.
  • The sharpest move saw R&D In Process skyrocketed 17165.33% in 2024, then plummeted 98.55% in 2025.
  • Over 5 years, R&D In Process stood at $89.0 million in 2021, then tumbled by 41.57% to $52.0 million in 2022, then soared by 1053.85% to $600.0 million in 2023, then crashed by 95.0% to $30.0 million in 2024, then surged by 4543.33% to $1.4 billion in 2025.
  • According to Business Quant data, R&D In Process over the past three periods came in at $1.4 billion, $633.0 million, and $1.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.